JP6543467B2 - 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途 - Google Patents

二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途 Download PDF

Info

Publication number
JP6543467B2
JP6543467B2 JP2014547146A JP2014547146A JP6543467B2 JP 6543467 B2 JP6543467 B2 JP 6543467B2 JP 2014547146 A JP2014547146 A JP 2014547146A JP 2014547146 A JP2014547146 A JP 2014547146A JP 6543467 B2 JP6543467 B2 JP 6543467B2
Authority
JP
Japan
Prior art keywords
heparin
chemically modified
glycosaminoglycan
molecular weight
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014547146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500388A5 (enExample
JP2015500388A (ja
Inventor
エイキュラ，ハンス−ペータ
エリクソン，ペル−オルブ
リンダール，ウルフ
ホルマー，エリック
Original Assignee
ディラホア アクチエボラゲット
ディラホア アクチエボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6543467(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ディラホア アクチエボラゲット, ディラホア アクチエボラゲット filed Critical ディラホア アクチエボラゲット
Publication of JP2015500388A publication Critical patent/JP2015500388A/ja
Publication of JP2015500388A5 publication Critical patent/JP2015500388A5/ja
Application granted granted Critical
Publication of JP6543467B2 publication Critical patent/JP6543467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014547146A 2011-12-19 2012-12-19 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途 Active JP6543467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
US61/577,223 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018034714A Division JP2018111825A (ja) 2011-12-19 2018-02-28 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途

Publications (3)

Publication Number Publication Date
JP2015500388A JP2015500388A (ja) 2015-01-05
JP2015500388A5 JP2015500388A5 (enExample) 2016-12-01
JP6543467B2 true JP6543467B2 (ja) 2019-07-10

Family

ID=48668970

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014547146A Active JP6543467B2 (ja) 2011-12-19 2012-12-19 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途
JP2018034714A Pending JP2018111825A (ja) 2011-12-19 2018-02-28 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018034714A Pending JP2018111825A (ja) 2011-12-19 2018-02-28 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途

Country Status (28)

Country Link
US (1) US9475888B2 (enExample)
EP (1) EP2794665B1 (enExample)
JP (2) JP6543467B2 (enExample)
KR (1) KR102135485B1 (enExample)
CN (1) CN104144950B (enExample)
AU (1) AU2012354229B2 (enExample)
BR (1) BR112014014454B1 (enExample)
CA (1) CA2856492C (enExample)
CL (1) CL2014001651A1 (enExample)
CO (1) CO7061069A2 (enExample)
CY (1) CY1119899T1 (enExample)
DK (1) DK2794665T3 (enExample)
ES (1) ES2656613T3 (enExample)
HR (1) HRP20180124T1 (enExample)
HU (1) HUE036523T2 (enExample)
IL (1) IL232905A (enExample)
LT (1) LT2794665T (enExample)
ME (1) ME02994B (enExample)
MX (1) MX351104B (enExample)
NO (1) NO2904345T3 (enExample)
PL (1) PL2794665T3 (enExample)
PT (1) PT2794665T (enExample)
RS (1) RS56874B1 (enExample)
RU (1) RU2617764C2 (enExample)
SI (1) SI2794665T1 (enExample)
SM (1) SMT201800143T1 (enExample)
WO (1) WO2013095279A1 (enExample)
ZA (1) ZA201403640B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
EP2830635A4 (en) * 2012-03-26 2016-03-16 Dilafor Ab COMBINATION TREATMENT OF ILLUSTRATED SULFATED GLYCOSAMINOGLYCANES
CN104244957B (zh) * 2012-03-26 2017-11-17 迪乐方有限责任公司 用于治疗分娩停止的方法
UA117912C2 (uk) * 2012-05-08 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для лікування післяпологової кровотечі (ппк)
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
EP3137509A4 (en) * 2014-04-30 2018-03-14 Agency For Science, Technology And Research Heparan sulphates
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
UA129730C2 (uk) 2020-02-17 2025-07-16 Дилафор Аб Тафоксипарин для лікування прееклампсії
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
JP2025514038A (ja) 2022-05-03 2025-05-02 ディラフォール アクチエボラグ タフォキシパリンの新規な医学的使用
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) * 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) * 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
ATE224918T1 (de) * 1995-03-31 2002-10-15 Hamilton Civic Hospitals Res Zusammensetzung zur hemmung der thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) * 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
JP3342007B2 (ja) * 1997-11-20 2002-11-05 郁男 山科 低分子ヘパリン修飾体及び皮膚潰瘍治療剤
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6498246B1 (en) 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1022289B1 (en) * 1998-07-31 2004-07-07 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
JP2002523522A (ja) * 1998-08-26 2002-07-30 ザ コラボレイティブ グループ，リミテッド． 非誘導化水溶性ベータ−（１，３）−グルカンのレセプター
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DK1319183T3 (da) * 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
MX2008000974A (es) * 2005-07-22 2008-03-27 Univ California Composiciones de heparina e inhibicion de selectina.
WO2007014155A2 (en) 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
AU2007233320B2 (en) * 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CN101495517B (zh) * 2006-05-25 2012-10-10 莫曼塔医药品有限公司 低分子量肝素及其用途
WO2009007224A1 (en) 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059283A1 (en) * 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8445436B2 (en) 2007-12-03 2013-05-21 Florida State University Research Foundation, Inc. Oxytocin and melatonin compositions and associated methods for inducing labor
CN102177180A (zh) 2008-04-04 2011-09-07 犹他州大学研究基金会 烷基化半合成的糖胺聚糖醚及其制备和使用方法
WO2010111570A1 (en) * 2009-03-27 2010-09-30 E. I. Du Pont De Nemours And Company Polyglycerol aldehydes
EP2419736B1 (en) 2009-04-16 2014-01-29 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
US20120108538A1 (en) 2009-06-30 2012-05-03 James Beeson Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
CA2769258A1 (en) * 2009-07-31 2011-02-03 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
BR112012015029A2 (pt) * 2009-12-22 2017-06-27 Lifebond Ltd matriz reticulada, método para controlar a formação de uma matriz, método ou matriz, método para vedar um tecido contra vazamento de um fluído corporal, agente hemostático ou vedante cirúrgico, composição para vedar um ferimento, uso da composição, composição para um veículo para entrega localizada de fármaco, composição para engenharia de tecido, e método para modificar uma composição
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104244957B (zh) 2012-03-26 2017-11-17 迪乐方有限责任公司 用于治疗分娩停止的方法
EP2830635A4 (en) 2012-03-26 2016-03-16 Dilafor Ab COMBINATION TREATMENT OF ILLUSTRATED SULFATED GLYCOSAMINOGLYCANES

Also Published As

Publication number Publication date
RU2014129816A (ru) 2016-02-20
EP2794665A1 (en) 2014-10-29
ME02994B (me) 2018-10-20
ZA201403640B (en) 2017-06-28
HRP20180124T1 (hr) 2018-02-23
MX2014007122A (es) 2015-03-05
AU2012354229A1 (en) 2014-06-05
PL2794665T3 (pl) 2018-04-30
HK1202883A1 (en) 2015-10-09
DK2794665T3 (da) 2018-01-29
IL232905A0 (en) 2014-07-31
RU2617764C2 (ru) 2017-04-26
US20150011505A1 (en) 2015-01-08
KR20140113652A (ko) 2014-09-24
MX351104B (es) 2017-10-02
BR112014014454A2 (pt) 2017-06-13
JP2018111825A (ja) 2018-07-19
IL232905A (en) 2017-02-28
CO7061069A2 (es) 2014-09-19
CA2856492C (en) 2017-01-10
KR102135485B1 (ko) 2020-07-17
RS56874B1 (sr) 2018-04-30
LT2794665T (lt) 2017-12-27
ES2656613T3 (es) 2018-02-27
EP2794665B1 (en) 2017-11-22
SI2794665T1 (en) 2018-03-30
CL2014001651A1 (es) 2014-10-10
WO2013095279A1 (en) 2013-06-27
US9475888B2 (en) 2016-10-25
SMT201800143T1 (it) 2018-05-02
PT2794665T (pt) 2018-01-24
EP2794665A4 (en) 2015-08-26
JP2015500388A (ja) 2015-01-05
CN104144950B (zh) 2017-09-05
CN104144950A (zh) 2014-11-12
CA2856492A1 (en) 2013-06-27
BR112014014454B1 (pt) 2021-03-09
HUE036523T2 (hu) 2018-07-30
AU2012354229B2 (en) 2016-12-01
CY1119899T1 (el) 2018-06-27
NO2904345T3 (enExample) 2018-07-21

Similar Documents

Publication Publication Date Title
JP6543467B2 (ja) 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途
DK176524B1 (da) Blandinger af sulfaterede polysaccharider samt fremstilling og anvendelse deraf
JP6703806B2 (ja) 低抗凝固剤ヘパリン
CA2868479A1 (en) Method for treatment of labor arrest
CN104203256B (zh) 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗
JP6378328B2 (ja) 化学修飾ヘパリンの製造のための新規プロセス
US20150099703A1 (en) Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
HK1202883B (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20161012

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20161020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190617

R150 Certificate of patent or registration of utility model

Ref document number: 6543467

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250